Instead, we speculate that anti-EGFR/VEGFR2 BsAb exerts its anti-tumor activity in our in-vivo mouse study via inhibition of EGFR signaling and disruption of autocrine and/or paracrine mechanisms modulated by VEGF/VEGFR2, which further supports our findings from cellular models. This evidence concerns the gene KDR and neoplasm.